Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 1/2 6Phase 1 5Phase NA 4Phase 3 4Phase 4 1

Status

Recruiting 9Completed 9Active not recruiting 9Terminated 5Unknown 4Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Breast Neoplasms 143Colorectal Neoplasms 97Carcinoma, Non-Small-Cell Lung 97Carcinoma, Hepatocellular 69Stomach Neoplasms 65Rectal Neoplasms 54Neoplasms 53Lung Neoplasms 45Colonic Neoplasms 41Nasopharyngeal Carcinoma 39Leukemia, Myeloid, Acute 39Prostatic Neoplasms 38Lymphoma, Large B-Cell, Diffuse 38Uterine Cervical Neoplasms 36Neoplasm Metastasis 33Ovarian Neoplasms 32Esophageal Neoplasms 32Multiple Myeloma 31Lymphoma 31Lymphoma, Follicular 30Leukemia 28Pancreatic Neoplasms 27Recurrence 22Head and Neck Neoplasms 22Brain Neoplasms 21Urinary Bladder Neoplasms 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, Non-Hodgkin 19Squamous Cell Carcinoma of Head and Neck 17Lymphoma, Mantle-Cell 17

Interventions

Gemcitabine 2toripalimab 1Vitamin B 12 1Pemetrexed 1Injections 1Folic Acid 1Dexamethasone 1Cisplatin 1Carboplatin 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Unknown × Carcinoma, Transitional Cell × Clear all
NCT04568304 2020-09-29

A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Shanghai Junshi Bioscience Co., Ltd.

Phase 3 Unknown
364 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT03296306 2017-09-28

FOCUS

Asan Medical Center

Phase 3 Unknown
330 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03193788 2017-06-21

PREMIER

Asan Medical Center

Phase 3 Unknown
74 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms

NCT00146276 2006-09-27

Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer

Association of Urologic Oncology (AUO)

Phase 3 Unknown
178 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡